Given the strong public policy in favor of settlements, companies should not be reluctant to enter into legitimate agreements that might appear anticompetitive—as long as they can present solid arguments that they were entered in good faith, especially if the agreements increase consumers' access to the drug in dispute. Legitimate licensing agreements are acceptable. Sham licensing is not.